This biotech company was relatively unknown a few years ago.Even in hindsight, it would have been difficult to predict Summit Therapeutics' (SMMT 2.88%) exceptional rise over the past three years. The company's shares have skyrocketed by more than 1,500% over this period. That's impressive even by the standards of the volatile biotech industry. Now looking forward, great things seem to be awaiting the biotech.Let's discuss why Summit Therapeutics is still worth investing in today.The "Keytruda killer"Why ha ...

Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the best biotech stocks to buy. On September 16, H.C. Wainwright reaffirmed its $50 price target and Buy rating for Summit Therapeutics Inc. (NASDAQ:SMMT). The firm emphasized that Summit’s ivonescimab, a PD-1 x VEGF bispecific antibody, has accomplished clinical milestones that are unprecedented in PD-1 medicines, including improved results in the HARMONi-2 trial conducted in China. H.C. Wainwright believes that investors now have a “highly risk-mitigat ...

Core Insights - Merck's Keytruda (pembrolizumab) has received FDA approval for a subcutaneous formulation, Keytruda Qlex, which is expected to launch commercially later this month [1][2] - The subcutaneous version offers improved patient convenience, reducing administration time from at least 30 minutes for the IV version to as little as one minute [2] - The approval is backed by pivotal studies showing that Keytruda Qlex is at least as effective as the IV formulation, with a regulatory filing for the SC version also under review in Europe [3] Group 1: Keytruda Qlex Approval and Market Impact - The approval of Keytruda Qlex is timely as Merck faces the potential loss of exclusivity for Keytruda IV in 2028, which currently accounts for over 48% of the company's revenue [4] - Keytruda IV generated over $15 billion in sales during the first half of 2025, reflecting an 8% year-over-year increase [4] - The new SC version comes with its own patents that extend protection beyond 2028, allowing Merck to manage Keytruda's lifecycle effectively [5] Group 2: Challenges and Competitive Landscape - Merck is experiencing a decline in sales of its second-largest product, Gardasil, which has dropped 48% year over year due to weak demand in China [6] - Competitive pressure for Keytruda may increase from dual PD-1/VEGF inhibitors like Summit Therapeutics' ivonescimab, which has shown potential to outperform Keytruda [9][10] - Merck is actively pursuing innovative combinations and partnerships, including a collaboration with Moderna to develop a personalized mRNA therapeutic cancer vaccine [8] Group 3: Financial Performance and Valuation - Merck's shares have underperformed the industry year to date, with a current price/earnings (P/E) ratio of 8.67, lower than the industry average of 14.88 and its 5-year mean of 12.70 [11][13] - Movements in EPS estimates for 2025 and 2026 have been mixed over the past 60 days, indicating uncertainty in future earnings [15] - Merck currently holds a Zacks Rank 3 (Hold), reflecting a cautious outlook [16]

Accessibility StatementSkip Navigation HONG KONG, Sept. 22, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK)Â has announced that the first patient has been dosed in its registrational Phase II study (AK130-202), evaluating AK130, a fully independently developed TIGIT/TGF- bifunctional antibody fusion protein, in combination with ivonescimab (PD-1/VEGF bispecific antibody), for treating locally advanced or metastatic pancreatic cancer in patients who have failed up to two prior lines of systemic therapy. AK130 is t ...

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Summit Therapeutics Inc. stands amongst them. Summit Therapeutics Inc. (NASDAQ:SMMT), a biopharmaceutical company focused on non-small cell lung cancer (NSCLC), has made significant strides with its lead investigational drug, ivonescimab. The HARMONi Phase III trial for EGFR-mutated NSCLC patients demonstrated a statistically significant improvement in progression-free survival when ivonescimab was combined ...

LOS ANGELES, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Summit Therapeutics Inc. investors  ("Summit" or the "Company") (NASDAQ: SMMT) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.  Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via https://portnoylaw.com/summit-therapeutics-in ...

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Summit and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May ...

Today, investors will closely monitor the Bureau of Labor Statistics’ release of its preliminary benchmark revision to payrolls for the year through March. The figure is expected to show another downward revision to March payrolls, suggesting the labor market was weakening well before the recent spell of sluggish job growth. Wells Fargo, Comerica Bank, and Pantheon Macroeconomics economists expect the revision to show that the March payroll count was nearly 800,000 lower than currently estimated, or about 6 ...

Core Viewpoint - CITIC Securities maintains a target price of HKD 177 for CanSino Biologics (09926) and a "outperform" rating following the positive trends observed in the global Phase III Harmoni study data for ivonescimab in treating second-line EGFR+ non-small cell lung cancer (NSCLC) [1] Group 1 - The Harmoni study data shows an improvement in overall survival (OS) risk trend from 0.79 to 0.78 [1] - The risk ratios reported for North America and Asia subgroups are 0.7 and 0.76, respectively, indicating strong performance [1] - The next key catalyst to watch is the results from the Phase III head-to-head clinical trial of Harmoni-6 versus tislelizumab, which will be presented at the 2025 European Society for Medical Oncology (ESMO) [1]

Core Viewpoint - Citic Securities maintains a target price of HKD 177 for Kangfang Biopharma (09926) and a "outperform" rating, following the positive trends observed in the global Phase III Harmoni study data for ivonescimab in treating second-line EGFR+ non-small cell lung cancer (NSCLC) [1] Group 1 - The Harmoni study showed an improvement in overall survival (OS) risk trend from 0.79 to 0.78, with risk ratios reported at 0.7 for North America and 0.76 for Asia, indicating strong performance [1] - The next anticipated catalyst is the presentation of results from the Harmoni-6 head-to-head Phase III trial against tislelizumab at the 2025 European Society for Medical Oncology (ESMO) [1]